Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>Events>This Event
  Events - January 2013


LC/MS Fundamentals and Applications

15 Jan 2013 - 21 Feb 2013 - Live-on-the-web



Bookmark and Share


This comprehensive overview course provides relevant, practical approaches that you can immediately apply in the lab. We cover some mass spectrometry and LC interface theory, however, the real focus is on improving your ability to use LC/MS on a daily basis.

Who Should Attend: Researchers, practitioners, technicians and others who are currrently using or plan to use LC, LC/MS, or data prduced by LC/MS.

This Live-on-the-web format covers 3 days of instruction over a 6 week period. The class meets over the internet twice a week for approximately 90 minutes per session and each session is recorded. This course is also available in Self-Paced and classroom formats. This course may also be customized for in-house presentation at your facility. Click here to learn more and register

How You'll Benefit:

  • Understand LC, MS and LC/MS interface operational fundamentals
  • Receive an LC/MS applications overview for pharma, biotech, chemical, forensic and toxicology
  • Learn how to modify and optimize HPLC methods for LC/MS
  • See how to use LC/MS to obtain qualitative information about your samples


Further information
Scientific News
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Researchers Find Key Player in Diabetic Kidney Disease Through Power of Metabolomics
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!